Categories: ImplantsNewsRobotics

Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.

Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:

Wednesday, August 14, 2024

Time:

4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Registration Link:

https://streamyard.com/watch/b2wwqt5vfh9E

The conference call will be broadcast live and available for replay to those who register via the above registration link.

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress implants. Monogram currently plans to apply for 510(k) clearance for its robotic products in the second half of 2024. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

To learn more, visit monogramtechnologies.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company’s statement regarding the Company’s proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company’s other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations

Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
MGRM@mzgroup.us

SOURCE: Monogram Technologies Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Houston Medical Waste Disposal Company Tackles Piercing Surge in Needlestick Injuries With Essential Guide

The CDC has reported an estimated 385,000 incidents of needlestick and sharps-related injuries among healthcare…

3 hours ago

Bayer and Alara Imaging Announce Collaboration

Collaboration brings together solutions with Bayer’s Calantic™ Digital Solution PlatformORLANDO, Fla.--(BUSINESS WIRE)--As Radiology administrators from…

6 hours ago

cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2024 Results

Charlotte, North Carolina--(Newsfile Corp. - August 5, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American:…

6 hours ago

Glytec Recognizes CMS for New Mandatory Hyper- and Hypoglycemia Measures for U.S. Hospitals

CMS Ground-Breaking Advancement in Diabetes Excellence Supported by Glytec Glucose Management Platform BOSTON, Aug. 5,…

6 hours ago

Services PMI® at 51.4%; July 2024 Services ISM® Report On Business®

Business Activity Index at 54.5%; New Orders Index at 52.4%; Employment Index at 51.1%; Supplier…

6 hours ago